Faculty of Medicine, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, Canada.
Division of Digestive Care and Endoscopy, Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.
Clin Transl Gastroenterol. 2020 Nov;11(11):e00258. doi: 10.14309/ctg.0000000000000258.
Hereditary hemochromatosis is an autosomal recessive disorder of iron absorption, leading to organ dysfunction. C282Y gene homozygosity is implicated in 80%-95% of cases of hereditary hemochromatosis. The clinical penetrance of this genotype remains unclear. The purpose of the study was to better describe the clinical penetrance and disease progression of C282Y homozygotes.
This is a retrospective study of all individuals in Newfoundland and Labrador, Canada, homozygous for the C282Y mutation from 1999 to 2009. Using electronic health records, laboratory values, phlebotomy status, radiologic reports, and clinic records were recorded up to November 2017. Iron overload status was classified via the HealthIron study. SPSS Version 19.0 (IBM Corporation) was used for descriptive statistics. Predictors of disease penetrance were assessed with logistic regression; a Student t test was used for continuous variables, and χ tests were used for categorical variables.
Between 1999 and 2009, 360 individuals tested positive for C282Y/C282Y. The mean age of diagnosis was 49.1 years. Three hundred six individuals had adequate follow-up for analysis (mean 11.6 years). End-organ damage was observed in 18.3%, with 5.8% developing liver disease. End-organ damage was more frequently observed in men 24.3% vs 10.5% (P < 0.05). Clinical penetrance in postmenopausal women approached that of men 18.3%.
This is the largest reported cohort of C282Y homozygotes, followed for an extended duration of time in North America. The findings reflect outcomes in routine clinical practice and suggest that C282Y homozygosity uncommonly causes end-organ damage and liver disease.
遗传性血色素沉着症是一种铁吸收的常染色体隐性遗传病,可导致器官功能障碍。C282Y 基因纯合子与 80%-95%的遗传性血色素沉着症病例有关。这种基因型的临床外显率尚不清楚。本研究的目的是更好地描述 C282Y 纯合子的临床外显率和疾病进展。
这是一项针对 1999 年至 2009 年期间加拿大纽芬兰和拉布拉多省所有 C282Y 突变纯合子个体的回顾性研究。通过电子健康记录、实验室值、放血状态、放射学报告和临床记录,截至 2017 年 11 月进行了记录。铁过载状态通过 HealthIron 研究进行分类。使用 SPSS 版本 19.0(IBM 公司)进行描述性统计。使用逻辑回归评估疾病外显率的预测因素;使用学生 t 检验评估连续变量,使用 χ 检验评估分类变量。
1999 年至 2009 年间,360 名个体的 C282Y/C282Y 检测结果呈阳性。诊断时的平均年龄为 49.1 岁。306 名个体有足够的随访分析(平均 11.6 年)。观察到 18.3%的终末器官损伤,其中 5.8%发生肝脏疾病。男性中观察到更多的终末器官损伤 24.3%比 10.5%(P<0.05)。绝经后女性的临床外显率接近男性 18.3%。
这是北美报道的最大的 C282Y 纯合子队列,随访时间较长。这些发现反映了常规临床实践中的结果,并表明 C282Y 纯合子很少引起终末器官损伤和肝脏疾病。